GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (OTCPK:ROQAF) » Definitions » Common Stock

ROQAF (Roquefort Therapeutics) Common Stock : $1.64 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Roquefort Therapeutics Common Stock?

Roquefort Therapeutics's quarterly common stock increased from Jun. 2023 ($1.63 Mil) to Dec. 2023 ($1.64 Mil) and increased from Dec. 2023 ($1.64 Mil) to Jun. 2024 ($1.64 Mil).

Roquefort Therapeutics's annual common stock increased from Dec. 2021 ($0.96 Mil) to Dec. 2022 ($1.57 Mil) and increased from Dec. 2022 ($1.57 Mil) to Dec. 2023 ($1.64 Mil).


Roquefort Therapeutics Common Stock Historical Data

The historical data trend for Roquefort Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Common Stock Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Common Stock
0.96 1.57 1.64

Roquefort Therapeutics Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23 Jun24
Common Stock Get a 7-Day Free Trial 0.89 1.57 1.63 1.64 1.64

Roquefort Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Roquefort Therapeutics Business Description

Traded in Other Exchanges
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines